{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T02:47:01Z","timestamp":1778986021849,"version":"3.51.4"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["J Addict Med"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:p>High-potency synthetic opioids and adulterants have saturated the US opioid supply, heightening risk to people who use drugs and creating challenges to buprenorphine initiation. As buprenorphine is an essential component of a response to the opioid crisis, a robust evidence base is urgently needed. Rapid research, in partnership with people who use drugs and using community-based participatory research practices to ensure trust, shared goals, and an absence of adverse consequences, should be conducted to help identify the factors associated with successful and failed inductions. Among factors to be considered include detailed assessment of substances used, amount of substances used, time between last use and buprenorphine induction, withdrawal severity at time of buprenorphine induction, dose of buprenorphine, impact of buprenorphine on withdrawal severity, and perhaps even genotypic information. Successful conduct of these efforts in learning health systems can help us move toward precision medicine for opioid use disorder.<\/jats:p>","DOI":"10.1097\/adm.0000000000001007","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T20:00:08Z","timestamp":1664308808000},"page":"e348-e349","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Buprenorphine Initiation in the Era of High-potency Synthetic Opioids: A Call for Community-based Participatory Research to Help Learning Health Systems Provide Precision Medicine for Opioid Use Disorder"],"prefix":"10.1097","volume":"16","author":[{"given":"David A.","family":"Fiellin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,9,27]]},"reference":[{"issue":"10","key":"bib1-20250526","doi-asserted-by":"crossref","first-page":"271","DOI":"10.15585\/mmwr.mm6910a4","article-title":"Notes from the field: opioid-involved overdose deaths with fentanyl or fentanyl analogs detected\u201428 states and the District of Columbia, July 2016\u2013December 2018","volume":"69","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"bib2-20250526","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1136\/injuryprev-2020-043968","article-title":"Increasing presence of xylazine in heroin and\/or fentanyl deaths, Philadelphia, Pennsylvania, 2010\u20132019","volume":"27","year":"2021","journal-title":"Inj Prev"},{"issue":"10","key":"bib3-20250526","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1002\/dta.3115","article-title":"Metonitazene in the United States\u2014forensic toxicology assessment of a potent new synthetic opioid using liquid chromatography mass spectrometry","volume":"13","year":"2021","journal-title":"Drug Test Anal"},{"key":"bib4-20250526","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.drugpo.2019.09.003","article-title":"\u201cEverything is not right anymore\u201d: buprenorphine experiences in an era of illicit fentanyl","volume":"74","year":"2019","journal-title":"Int J Drug Policy"},{"key":"bib5-20250526","article-title":"A Plea from people who use drugs to clinicians: new ways to initiate buprenorphine are urgently needed in the fentanyl era","volume":"Publish Ahead of Print","year":"2022","journal-title":"J Addict Med"},{"issue":"3","key":"bib6-20250526","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jsat.2008.06.006","article-title":"Factors affecting willingness to provide buprenorphine treatment","volume":"36","year":"2009","journal-title":"J Subst Abuse Treat"},{"issue":"5","key":"bib7-20250526","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/ADM.0000000000000059","article-title":"Unobserved \u201chome\u201d induction onto buprenorphine","volume":"8","year":"2014","journal-title":"J Addict Med"},{"key":"bib8-20250526","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.neubiorev.2018.12.005","article-title":"Fentanyl: receptor pharmacology, abuse potential, and implications for treatment","volume":"106","year":"2019","journal-title":"Neurosci Biobehav Rev"},{"key":"bib9-20250526","first-page":"283","article-title":"Treating opioid withdrawal in the hospital: a role for short-acting opioids","volume":"175","year":"2021","journal-title":"Ann Intern Med"},{"issue":"2 Suppl","key":"bib10-20250526","first-page":"S13","article-title":"The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic","volume":"70","year":"2003","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"bib11-20250526","first-page":"S59","article-title":"Buprenorphine: how to use it right","volume":"70","year":"2003","journal-title":"Drug Alcohol Depend"},{"issue":"2\u20133","key":"bib12-20250526","first-page":"261","article-title":"Sublingual buprenorphine\/naloxone precipitated withdrawal in subjects maintained on 100 mg of daily methadone","volume":"90","year":"2007","journal-title":"Drug Alcohol Depend"},{"key":"bib13-20250526","first-page":"263","article-title":"A review of the pharmacogenomics of buprenorphine for the treatment of opioid use disorder","volume":"4","year":"2020","journal-title":"J Transl Genet Genom"},{"issue":"2","key":"bib15-20250526","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1370\/afm.2042","article-title":"The PCORI engagement rubric: promising practices for partnering in research","volume":"15","year":"2017","journal-title":"Ann Fam Med"},{"key":"bib16-20250526","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.socscimed.2017.01.027","article-title":"Community-based participatory research in a heavily researched inner city neighbourhood: perspectives of people who use drugs on their experiences as peer researchers","volume":"176","year":"2017","journal-title":"Soc Sci Med"},{"issue":"1","key":"bib17-20250526","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12954-019-0315-5","article-title":"Research 101: a process for developing local guidelines for ethical research in heavily researched communities","volume":"16","year":"2019","journal-title":"Harm Reduct J"},{"issue":"1","key":"bib18-20250526","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12954-019-0306-6","article-title":"Achieving meaningful participation of people who use drugs and their peer organizations in a strategic research partnership","volume":"16","year":"2019","journal-title":"Harm Reduct J"}],"container-title":["Journal of Addiction Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ADM.0000000000001007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T20:08:14Z","timestamp":1748290094000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/ADM.0000000000001007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,27]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/adm.0000000000001007","relation":{},"ISSN":["1932-0620"],"issn-type":[{"value":"1932-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,27]]}}}